w4i
wings4innovation facilitates translation of biomedical innovation in Austria
Call for Proposals: If you have research results supporting a clear hypothesis for an innovative therapy in indications with high unmet need, please apply.

wings4innovation and KHAN technology transfer fund provide a new translation and financing paradigm for innovative drug discovery proposals from Austrian academic institutes and SMEs.

Team
Our Team

Dr. Peter Nussbaumer
Peter has about 35 years of industry experience in medicinal chemistry and drug discovery. Since 2008, he is Managing Director and Head of Medicinal Chemistry at the Lead Discovery Center GmbH (LDC) in Dortmund, Germany and since 2019 also Managing Director of the wings4innovation GmbH in Vienna. Both organisations operate at the interface of academia and industry. Before joining LDC, Peter was Executive Director at the Novartis Institutes for BioMedical Research in Vienna, Austria, heading the Chemistry Department. During his 23 years at Sandoz/Novartis, he held various positions in the area of medicinal chemistry and interdisciplinary project leadership.
Peter is member of several international scientific advisory boards and serves as advisor to private and public funding bodies. He is (co)author of more than 80 peer-reviewed publications and more than 25 patent applications, referee to various journals, and holds a Dr. degree in organic chemistry from the TU Wien, Austria.

Dr. Wolfgang Sommergruber
Wolfgang Sommergruber studied Biochemistry at the University of Vienna, Austria, and received his Magister in 1981 and his Ph.D. in 1985. During the time as a Postdoc at the Institute of Biochemistry (Medical Faculty) and a short- term research fellowship at Stony Brook University, New York, his scientific focus was on the molecular characterization of the proteolytic processing of picornaviruses. In 1986 he joined as a lab head Boehringer Ingelheim in Vienna, Austria, where he performed research on viral and tumor-associated proteases. These studies served as the basis for his habilitation thesis, and Wolfgang received the „Venia Docendi“ for Medical Biochemistry in 2000.
From 2002 till 2019 he worked as a Scientific Director in the Dept. of Exploratory Research Oncology at Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria. During this time Wolfgang performed translational research on the transcriptional control of interferon genes and the identification of novel tumor-associated antigens by combination of subtractive libraries with cDNA microarrays.
Later on, Wolfgang aimed at the identification of novel drug intervention sites in oncology including targets in tumor metabolism, tumor-stroma crosstalk, epigenetic targets in immune-oncology and immunogenic cell death. Since 2019 he is Visiting Professor at University of Applied Sciences, Vienna, Austria.
Wolfgang got several awards and was leader and co-leader in international and national research programs such as GEN-Au (Austrian Genomic Research Program – „Genomic Approaches to Tumor Invasion and Metastasis“; 2002-2006) and IMI (Innovative Medicines Initiative – „New tools for target validation to improve drug efficacy“ embedded in the European FP7 program; 2011-2016). Wolfgang is (co)author of 80 peer-revied publications and 9 book chapters. He was invited for lectures at 50 international and national congresses. In 2021 he joined wings4innovation GmbH as Translational Guide.
Proposals
Call for Proposals
After a successful financing of 10 Austrian projects and two company investments in Austria in the portfolio of KHAN-I, KHAN-II has started. Researchers from Austrian academic institutes and SMEs can apply with their ideas until the end of 2029.
If you have research results supporting a clear hypothesis for an innovative therapy in indications with high unmet need, please apply!


Who we are
wings4innovation GmbH (w4i) is a subsidiary of KHAN Technology Transfer Fund I GmbH & Co. KG (KHAN-I).
w4i scouts and evaluates project ideas and proposes suitable projects for KHAN funding. w4i is the central contact for academic/SME partners from all over Austria.

Requirements for funding
- Findings & hypotheses that may lead to an innovative therapy (small molecules, biologics, …) in indications with high unmet medical need
- In-depth scientific know-how at Principal Investigator (PI)
- Preexisting IP is not a prerequisite
- Technical feasibility, chance for commercialisation
- Approval by the w4i Advisory Board and the KHAN Investment Advisory Committee
- Close collaboration between w4i/KHAN and PI
News
News
Follow us on Linkedin for recent advances
Portfolio
Portfolio

Partners
Framework Collaboration Partners
